Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.
Accepted 2026-02-10 00:00:00 ET · period of report 2026-02-06 · accession 0001500189-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-10 | 2026-02-06+ | ZNTL | EASTLAND JULIA MARIE | CEO, Pres, Dir | S - Sale | $2.43 | -8,755 | 79.1K | -10% | -$21.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-06 | S | D | 7,866 | $2.43 | 80,022 | D | — | — | (F1) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. |
| 2 | Common | Common Stock | 2026-02-09 | S | D | 889 | $2.39 | 79,133 | D | — | — | (F1) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. |